Over the past few years, the company has been on a journey to reshape itself into a more growth-oriented and innovative biopharma company, Pfizer said in a regulatory filing. The Mumbai-based company, which has a portfolio of over 150 products across 15 therapeutic areas, noted that its products are more specialty-oriented and that requires it to adopt newer go-to-market models.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/w1ZmMJL
via IFTTT
0 comments:
Post a Comment